Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00885378 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 166
- Enrollment target
NCT00885378 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 166 participants.
The verdict
NCT00885378, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 166 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the reduction in hemoglobin A1C (A1C) for participants taking saxagliptin in combination with metformin immediate release (IR) versus metformin IR alone.
Interventions
- DRUG Saxagliptin plus metformin IR
- DRUG Placebo plus metformin IR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2009-05 |
| Est. Completion | 2010-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00885378
The ClinicalTrials.gov registry entry for NCT00885378 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 166 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saxagliptin plus metformin IR is the first listed.
NCT00885378 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00885378 about?
NCT00885378 is a clinical study titled "Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus". The purpose of this study is to compare the reduction in hemoglobin A1C (A1C) for participants taking saxagliptin in combination with metformin immediate release (IR) versus metformin IR alone.
What is the current status of trial NCT00885378?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 166 participants. The study started on 2009-05. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00885378?
The interventions under investigation include: Saxagliptin plus metformin IR (DRUG), Placebo plus metformin IR (DRUG).
Who is sponsoring clinical trial NCT00885378?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.